Total Return chart HK inno.N Corporation

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
37,650 ^KRW	-0.13%		+0.80%	-15.30%

2022	Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada	CI
2022	Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.